ストックスクリーナーアプリを入手
7.35
2.37%
0.17
アフターアワーズ：
7.25
-0.10
-1.36%
前日終値:
$7.18
開ける：
$7.03
24時間の取引高:
380.74K
Relative Volume:
0.25
時価総額：
$227.86M
収益：
-
当期純損益:
$-29.25M
株価収益率:
-6.1973
EPS:
-1.186
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
-15.22%
1か月 パフォーマンス:
-16.76%
6か月 パフォーマンス:
+78.40%
1年 パフォーマンス:
+138.64%
1日の値動き範囲:
$7.02
$7.40
1週間の範囲:
$6.5323
$8.64
52週間の値動き範囲:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
SGMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.35 | 245.54M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | 開始されました | Wedbush | Outperform |
| 2025-08-07 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-24 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - ca.finance.yahoo.com
Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy - TipRanks
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position - TipRanks
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Will earnings trigger a reversal in Sagimet Biosciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
How sentiment analysis helps forecast Sagimet Biosciences Inc.July 2025 Review & Capital Protection Trading Alerts - Newser
Real time scanner hits for Sagimet Biosciences Inc. explained2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
What data driven models say about Sagimet Biosciences Inc.’s futureShare Buyback & High Accuracy Swing Trade Signals - Newser
Is Sagimet Biosciences Inc. stock bottoming outInsider Buying & Free Verified High Yield Trade Plans - Newser
Sagimet Biosciences Inc. recovery potential after sell offWeekly Loss Report & Free Growth Oriented Trading Recommendations - Newser
Screener Results Flag Sagimet Biosciences Inc. as OversoldEarnings Growth Summary & Risk Controlled Stock Alerts - beatles.ru
News impact scoring models applied to Sagimet Biosciences IncEarnings Overview Report & Low Drawdown Trading Techniques - Newser
Is Sagimet Biosciences Inc. building a consolidation baseJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Earnings Miss & Real-Time Volume Trigger Notifications - Newser
News impact scoring models applied to Sagimet Biosciences Inc.July 2025 Outlook & Precise Trade Entry Recommendations - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityBull Run & Daily Risk Controlled Trade Plans - Newser
Will Sagimet Biosciences Inc. Benefit From Sector TailwindsTrade Signal Summary & Real-Time Volume Trigger Notifications - metal.it
A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛
Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating - TipRanks
Brokers Set Expectations for SGMT Q2 Earnings - Defense World
Sagimet Biosciences Advances FASN Inhibitor Trials for Acne and MASH, Reports Q2 Earnings - AInvest
Sagimet Biosciences Reports Progress in Acne and MASH Trials - TipRanks
Sagimet Biosciences Enters New Sales Agreement with Leerink - TipRanks
Sagimet Biosciences Reports Q2 Results and Clinical Progress - MSN
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners - Investing.com Canada
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners By Investing.com - Investing.com South Africa
Sagimet Biosciences, Inc. Class A: Promising Combination Therapy for MASH Drives Buy Rating - TipRanks
Sagimet Biosciences Tops Q2 EPS Forecast - AOL.com
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Q2 GAAP EPS Beats by $0.21, Cash Holdings at $135.5M - AInvest
Sagimet Biosciences: Navigating the High-Risk Biopharma Landscape with Operational Gains and Earnings Resilience - AInvest
Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq
Sagimet Reports Q1 Earnings, Advances Denifanstat and TVB-3567 Trials - AInvest
Sagimet Biosciences Inc. SEC 10-Q Report - TradingView
Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Wedbush Initiates Sagimet Biosciences at Outperform With $28 Price Target - MarketScreener
Wedbush initiates coverage on Sagimet Biosciences with Outperform rating and $28 PT. - AInvest
Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating - Investing.com Nigeria
Can Sagimet Biosciences Inc. Escape Recent Bear ChannelDay Trading Signals With High Precision Reviewed - beatles.ru
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - Defense World
What is HC Wainwright’s Estimate for SGMT Q2 Earnings? - Defense World
Sagimet Biosciences SGMT Q2 2025 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Sagimet Biosciences (NASDAQ:SGMT) Upgraded at HC Wainwright - Defense World
Is This a Bottoming Phase for Sagimet Biosciences Inc.Capital Protection Trading Strategies Gain Interest - beatles.ru
Can volume confirm reversal in Sagimet Biosciences Inc.Chart Driven Entry Timing for Swing Trades - Newser
Sagimet Biosciences Inc. Matches Institutional Buying FilterWeekly Chart Analysis With Entry Advice Provided - beatles.ru
How to recover losses in Sagimet Biosciences Inc. stockMachine Learning Intraday Signal Forecast - Newser
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
Sagimet Biosciences Inc (SGMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
1.55%
0.38%
大文字化:
|
ボリューム (24 時間):